This is the authors' abstract. We don't add key points for this paper.
may benefit patients with muscular dystrophies or other neuromuscular degenerative conditions characterized by the PARP/NNMT gene expression signatures.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ryu et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: